The efficacy and safety of dipyrone (Novalgin®) tablets in the treatment of acute migraine attacks: A double-blind, cross-over, randomized, placebo-controlled, multi-center study

Functional Neurology

Volumn 19, Issue 3, 2004, Pages 197-202

  Tulunay, F Cankat ^a   Ergün, Hakan ^a   Gülmez, Sinem Ezgi ^a   Özbenli, Taner ^b   Özmenoǧlu, Mehmet ^c   Boz, Cavit ^c   Erdemoglu, Ali Kemal ^d   Varlikbas, Adnan ^d   Göksan, Baki ^e   Inan, Levent ^f  

^a ANKARA UNIVERSITY   (Turkey)

^b ONDOKUZ MAYIS UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c BLACK SEA TECHNICAL UNIVERSITY   (Turkey)

^d KIRIKKALE UNIVERSITY   (Turkey)

^e ISTANBUL UNIVERSITY   (Turkey)

^f ANKARA NUMUNE HOSPITAL   (Turkey)

Author keywords

Acute treatment; Dipyrone; Migraine; Placebo

Indexed keywords

CAFERGOT; DIPYRONE; ERGOTAMINE; METOCLOPRAMIDE; PLACEBO;

ACUTE DISEASE; ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EXPERIMENTAL DESIGN; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; PAIN ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECURRENCE RISK; RISK REDUCTION; SCORING SYSTEM; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGED; ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHI-SQUARE DISTRIBUTION; CROSS-OVER STUDIES; DIPYRONE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; PAIN MEASUREMENT; SEVERITY OF ILLNESS INDEX;

EID: 20944443197     PISSN: 03935264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Rasmussen BK, Olesen J. Symptomatic and nonsymptomatic headaches in a general population. Neurology 1992;42:1225-1231
2. Cerbo R, Pesare M, Aurilia C, Rondelli V, Barbanti P. Socio-economic costs of migraine. J Headache Pain 2001; 2:S15-S19
3. Menken M, Munsat TL, Toole JF. The global burden of disease study: implications for neurology. Arch Neurol 2000;57:418-420
4. Tulunay FC, Tulunay O, Inan L, Ergun H. Quality of life survey in migraine in Turkish headache patients. Cephalalgia 2000;20:360 (abstract)
5. Massiou H, Serrurier D, Lasserre O, Bousser MG. Effectiveness of oral diclofenac in the acute treatment of common migraine attacks: a double-blind study versus placebo. Cephalalgia 1991;11:59-63
6. Dib M, Massiou H, Weber M, Henry P, Garcia-Acosta S, Bousser MG, and the Bi-Profenid Migraine Study Group. Efficacy of oral ketoprofen in acute migraine. Neurology 2002;58:1660-1665
7. Lance JW. Neuronal and humoral theories of the pathophysiology of migraine. Rationale for the use of calcium entry blocking agents. New Trends Clin Neuropharmacol 1987;1:69-77
8. Berge OG. Regulation of pain sensitivity, influence of prostaglandins. Cephalalgia 1986; 6(Suppl 4):21-31
9. Parantainen J, Vapaatalo H, Hokkanen E. Clinical aspects of prostaglandins and leukotriens in migraine. Cephalalgia 1986; 6(Suppl 4):95-101
10. Anthony M. The biochemistry of migraine. In: Rose FC ed Handbook of Clinical Neurology. Amsterdam; Elsevier Science Publishers 1986: 85-105
11. Curtis-Prior PB ed Handbook of Biology and Chemistry of Prostaglandins and Related Metabolites of Polyunsaturated Fatty Acids. Edinburgh; Churchill-Livingstone 1987
12. Novalgin®, Scientific Monograph; Hoechst 1996
13. Brogden RN. Pyrazolone derivatives. Drugs1986;32 (Suppl 4):60-70
14. Sabatowski R, Radbruch L, Grond S, Lehmann KA. The history of pain therapy. Ther Umsch 1999;56:423-425
15. Wong A, Sibbald A, Ferrero F et al. Antipyretic effects of dipyrone versus ibuprofen versus acetaminophen in children: results of a multinational, randomized, modified double blind study. Clin Pediatr 2001;40:313-324
16. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8:19-29
17. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000;20:765-786
18. Rasmussen BK, Olesen J. Migraine with aura and migraine with aura: an epidemiological study. Cephalalgia 1992;19:107-114
19. Launer LJ, Terwindt GM, Ferrari MD. The prevalence and characteristics migraine in a population-based cohort: the GEM study. Neurology 1999;53:537-542
20. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N Engl J Med 2002;346: 257-270
21. Snow V, Weiss K, Wall EM, Mottur-Pilson C. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med 2002; 137:840-849
22. Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Intravenous dipyrone in the acute treatment of migraine without aura and migraine with aura: a randomized, double-blind, placebo-controlled study. Headache 2002;42:862-871
23. Bigal ME. Intravenous dipyrone for the acute treatment of episodic tension-type headache: a randomized, placebo-controlled, double-blind study. Braz J Med Biol Res 2002;35:1139-1145
24. Bigal ME, Bordini CA, Speciali JG. Intravenous metamizol (dipyrone) in acute migraine treatment and in episodic tension-type headache - a placebo-controlled study. Cephalalgia 2001;21:90-95
25. Martinez-Martin P, Rafaelli E Jr, Titus F et al. and the Cooperative Study Group. Efficacy and safety of metamizol vs acetylsalicylic acid in patients with moderate episodic tension-type headache: a randomized, double-blind, placebo- and active-controlled, multicentre study. Cephalalgia 2001;21:604-610
26. Edwards JE, McQuay HJ. Dipyrone and agranulocytosis: what is the risk? Lancet 2002;360:1438-1439
27. Schönhöfer P, Offerhaus L, Herxheimer A. Dipyrone and agranulocytosis: what is the risk? Lancet 2003;361:968-969
28. Bensenor IM. To use or not to use dipyrone? Or maybe, Central Station versus ER? That is the question. Sao Paulo Med J 2001;119:190-191
29. Berlin C. Are we losing good drugs? Clin Pediatr (Phila) 2001;40:325-326
30. The International Agranulocytosis and Aplastic Anemia Study. Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. JAMA 1986,256:1749-1757
31. Baar HA, Brune K, Rust M. The use of dipyrone In: Brune K ed Dipyrone: Recent Investigations on its Mode of Action, Pharmacokinetics and Clinical Use. Basel; Birkhäuser 1992: 47-52
32. Andrade SE, Martinez C, Walker AM. Comparative safety evaluation of non-narcotic analgesics. J Clin Epidemiol 1998;51:1357-1365